



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
DESIGNATED/ELECTED OFFICERECIEVING OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. § 371

Applicant: FUNDYTUS, Marian E. et al.)) Attorney Docket:
U.S. Serial No.: 10/031,308)) 85286
Title: ANTISENSE OLIGONUCLEOTIDES))
FOR METABOTROPIC GLUTAMATE))
RECEPTOR TYPE 1 (MGLUR₁)) Confirmation No.:
Priority Application Information:)) 5768
Intl. App. No. PCT/CA00/00824))
Intl. Filing Date 17 July, 2000) DE/EO/US Examiner:
Priority Ser. No. US 60/144,004) Lamont M. Hunter
Priority Filed 12 July 1999))

BIOLOGICAL SEQUENCE LISTING STATEMENT

U.S. Patent and Trademark Office
BOX SEQUENCE
Post Office Box 2327
Arlington, Virginia 22202

Sir:

This Biological Sequence Listing Statement, being sent to Box Sequence in Arlington Virginia, is in response to the Notification of Defective Response mailed February 6, 2003 (a copy enclosed). Pursuant to 37 C.F.R. § 1.825, a substitute Sequence Listing (paper copy and CRF) is provided herewith for the subject patent application. A copy of this Biological Sequence Listing Statement and its enclosures is being transmitted under separate cover to Box PCT to show that a response to the Notification of Defective Response was timely filed. A copy of that Transmittal Letter to the United States Designated/Elected Office (DO/EO/US) Concerning a Filing under 35 U.S.C. § 371 is enclosed herewith.

A paper copy of the substitute Sequence Listing required under 37 C.F.R. § 1.821(c) is enclosed, the sheets of which include no new matter, as required under 37 C.F.R.

§ 1.825(a). The present substitute Sequence Listing is identical to the paper copy of the Biological Sequence Listing included in the original national phase filing papers under 37 C.F.R. § 371 filed January 14, 2002. These Sequence Listings have the same disclosed subject matter as the above-referenced International Patent Application, and thus does not include matter which goes beyond the discloser in the international application as filed.

A computer readable form (CRF) of the substitute Sequence Listing is enclosed, pursuant to 37 C.F.R. § 1.825(b), a substitute copy of the computer readable form (CRF), required by 37 C.F.R. § 1.821(e), is also provided.

As required under 37 C.F.R. § 1.821(f), the sequence listing information recorded in the accompanying CRF is identical to the sequence listing information recorded in the accompanying written paper copy of the "Sequence Listing".

It is respectfully noted that a paper copy of the Sequence Listing was provided with the original patent application filing papers in the U.S. under 35 U.S.C. § 371 on January 14, 2002, and that a CRF was provided on September 26, 2002. No Sequence Listing error report was submitted with the Notification of Defective Response noting deficiencies with the previously-filed CRF.


The enclosed CRF contains an identical copy of the sequence listing file, in ASCII output from PatentIn version 2.1 on a Windows 95/PC compatible computer, from our file copy previously-filed CRF . That file has been run through the PTO Checker program, and a copy of the output ("Verification Summary Report") is enclosed herewith, showing no errors reported for that sequence listing file. As such, pursuant to 37 C.F.R. § 1.825(d), the substitute data is identical to that originally filed.

No fee or petition is believed to be necessary. However, should any fee be needed, please charge our Deposit

Account No. 23-0920, and deem this paper to be the required petition.

The Examiner is requested to phone the undersigned should any questions arise that can be dealt with over the phone to expedite this prosecution.

Respectfully submitted,



Shannon L. Nebolsky, Reg. No. 41,217

Attorney for Applicants


US PTO Customer No. 24628
WELSH & KATZ, Ltd.
120 South Riverside Plaza
22nd Floor
Chicago, Illinois 60606
(312) 655-1500

Enclosures:

Copy of Transmittal Letter
Copy of Notification of Defective Response
Paper copy of Sequence Listing
CRF diskette
Verification Summary Report
Return postcard

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this Biological Sequence Listing Statement, together with the stated enclosures, is being deposited with the United States Postal Service Express Mail service in an envelope addressed to U.S. Patent and Trademark Office BOX SEQUENCE, Post Office Box 2327, Arlington, Virginia 22202, on February 27, 2003.



Darryl B. Jones

Darryl B. Jones



PAGE:
02/18/2003

1

VERIFICATION SUMMARY REPORT

DATE:

PATENT APPLICATION

TIME: 13:44:56

INPUT SEQ: C:\CHECKER\Datahold\OLIGOME1.APP

GENERAL INFORMATION SECTION

3,<110> Henry, James L
4, Fundytus, Marian E
5, Vaudreuil, Terrasse
7,<120> Oligonucleotide For Metabotropic Glutamate Receptor
8, Type 1 (MGLUR1)
10,<130> 457-107PCT
12,<140>
13,<141>
15,<150> 60/144,004
16,<151> 1999-07-15
18,<160> 39
20,<170> PatentIn Ver. 2.1

ERRORED LINES SECTION

STATISTICS SUMMARY

Application Serial Number:
Alpha or Numeric: Numeric
Application Class:
Application File Date:
Art Unit:
Software Application: PatentIN2.1
Total Number of Sequences: 39
Total Nucleotides: 699
Total Amino Acids: 0
Number of Errors: 0
Number of Warnings: 0
Number of Corrections: 0